

TAKE A STAND FOR LONGER SURVIVAL



Median Overall Survival²

9.3 Months
with Xospata

VS

5.6 Months
with salvage chemotherapy

HR=0.64 (95% CI: 0.49, 0.83); P < 0.001



Percentage of patients underwent transplantation²

25.5%
with Xospata
(n=63/247)

VS

15.3%
with salvage chemotherapy
(n=19/124)

Recommended by:³⁻⁵



GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

NICE National Institute for
Health and Care Excellence

Scan for efficacy data
of XOSPATA[®]



Abbreviations:

CI: confidence interval; FLT3: FMS-like tyrosine kinase 3; HR: hazard ratio; OS: overall survival

References:

1. Xospata[®] Prescribing Information Hong Kong 2. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. *N Engl J Med* 2019;381(18):1728-40 3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute myeloid leukemia (Version 2. 2021 -November) 4. Heuser M, et al. *Annals of Oncology*. 2020;31(6): 697-712. 5. NICE technology appraisal guidance. Available at: <https://www.nice.org.uk/guidance/ta642/resources/gilteritinib-for-treating-relapsed-or-refractory-acute-myeloid-leukaemia-pdf-82609134829765>, accessed on 22 Mar 2022.

Please find the abbreviated
prescribing information here:



Email us at PV@hk.astellas.com when there is any Adverse Event

Astellas Pharma Hong Kong Company Limited

Unit 1103-08, 11/F, Tower 1, Grand Century Place, 193 Prince Edward Rd. West, Mongkok, Kowloon, Hong Kong

Tel: (852) 2377 9801 | Fax: (852) 2856 1440 | Email: info@hk.astellas.com

AHK-XSP-202203-04